MAIA Biotechnology is a targeted therapy and an immune-oncology company focused on developing and commercializing first-in-class drugs with novel mechanisms of action intended to improve and extend people's lives with cancer meaningfully.

A privately-held company based in Chicago, MAIA is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials.

MAIA’s business strategy is designed to advance a strong value proposition for its potentially novel compounds portfolio. MAIA controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with various compounds with novel mechanisms of action that have potential activity in multiple tumor types.

MAIA’s business model involves placing drug candidates in their own dedicated, R&D-focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure.